Naringenin Sensitizes Resistant C6 Glioma Cells with a Repressive Impact on the Migrating Ability

Background: Glioma, the most common form of a malignant brain tumour is characterised by a poor prognosis, which is attributable to its resistance against current therapeutic approaches. Temozolomide (TMZ), a DNA alkylating agent, is the first-line drug for glioma treatment. Long-term treatment usin...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of Neurosciences 2020-07, Vol.27 (3-4), p.114-123
Hauptverfasser:	J, Jayalakshmi, Vanisree, Arambakkam Janardhanam
Format:	Artikel
Sprache:	eng
Schlagworte:	Original
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!